Published November, 2010
By Nicholas B. La Thangue and Lasantha R. Bandara
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

---

Published November, 2010
By David E. Fisher
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Leading-edge and forward-looking, Tumor Suppressor Genes in Human Cancer illuminates what is currently known of tumor suppressor genes and their regulation, work that is already beginning to revolutionize cancer target elucidation, drug discovery, and treatment design.

---

Published November, 2010
By Beverly A. Teicher
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered.

---

Published November, 2010
By John A. Hickman and Caroline Dive
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The past few years have witnessed an astonishing international effort that established the role of some 20 new molecules in apoptosis and added activation or suppression of apoptosis to the accepted biological functions of a great many others already familiar in cancer biology.

---

Published November, 2010
By Godefridus J. Peters
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The classical example is gemcitabine, now one of the most widely applied deoxynucleoside analogs, used for the (combination) treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer, and ovarian cancer.

---

Published November, 2010
By Julian Adams
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Takes stock of the work that has been accomplished with proteasome inhibitors in cancer, and examines various therapeutic possibilities. This title covers topics ranging from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of clinical trials underway.

---

Published November, 2010
By Sonia Jakowlew, Carl-Henrik Heldin, Sonia B. Jakowlew and C.-H. Heldin
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Transforming Growth Factor- ss in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ss (TGF- ss) in cancer treatment and therapy. The companion volume details the role of TGF- ss on basic and clinical biology.

---

Published November, 2010
By Antonio Giordano and Kenneth J. Soprano
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Leading clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell cycle control and demonstrate its clinical relevance to understanding neoplastic diseases.

---

Published November, 2010
By Youcef M. Rustum
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.

---

Published November, 2010
By Michel Page
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

---